Nelson Research's Dexan
Executive Summary
Sandoz obtains U.S. and Canadian marketing rights to the irritable bowel syndrome product. Nelson noted that the final phase of clinical trials on Dexan was initiated this spring and an NDA is expected to be filed with FDA in 1986.